Gut Microbiota and Metabolic Disease Pathogenesis

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Gut Microbiota".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 1874

Special Issue Editor


E-Mail Website
Guest Editor
Centre for Cardio-Metabolic Research in Africa (CARMA), Division of Medical Physiology, Stellenbosch University, Stellenbosch, South Africa
Interests: mitochondrial research; bioenergetics; metabolism; animal models; gut microbiota; cardiometabolic diseases

Special Issue Information

Dear Colleagues,

The gut microbiota, referring to the rich and complex set of microorganisms that reside in the human gastrointestinal tract, has been underestimated as a key player in health and disease. However, in the last decade, a plethora of studies have demonstrated the instrumental involvement of the gut microbiota in the physiological homeostasis of a healthy gut and the pathogenesis of a myriad of diseases. In addition, accumulating evidence suggests that gut microbiota is also a rich source of novel therapeutic targets and may, therefore, aid personalized and precision microbiome therapies. More research is needed to better understand the gut microbiota profile and how its dynamics (structural, morphological, and anatomical changes; eubiosis; and dysbiosis) are affected by host genetics or environmental factors, such as diet, medications, or pollution. Against this background, more can be discovered about the gut microbiota in terms of transcriptomics, proteomics, metabolomics, mitochondrial bioenergetics, metabolism, and signaling. Furthermore, much remains to be elucidated regarding the gut–brain axis, neuroactive microbes, cardio-pulmonary vascular diseases, metabolic diseases, cancer, and immuno-oncology.

Therefore, in this Special Issue, we will focus on research questions that aim to better understand the topics mentioned above. We are pleased to invite your valuable scientific contributions in the form of original research articles or reviews.

We look forward to receiving your contributions.

Dr. Gerald Maarman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiota dynamics (structural/morphological/anatomical changes, eubiosis, and dysbiosis)
  • exploring healthy gut microbiota
  • gut microbiota, host genetics, and epigenetics
  • gut microbiota shotgun metagenomics, single-cell sequencing, CRISPR editing, and spatial profiling
  • transcriptomics, proteomics, and metabolomics
  • mitochondrial bioenergetics and metabolism
  • mitochondrial signaling
  • personalized and precision microbiome therapies
  • microbial metabolites as therapeutics
  • gut–brain axis and neuroactive microbes
  • gut–brain axis in cardio-pulmonary vascular diseases
  • gut involvement in metabolic diseases
  • gut microbiota in immune-oncology and cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1084 KB  
Review
Managing Gut Dysbiosis: Clinical Evidence and Perspectives on Saccharomyces boulardii CNCM I-745 for Diarrhoeal Conditions in Adults and Children
by Gerardo Pio Nardone, Arrigo Francesco Giuseppe Cicero, Luca Gallelli and Roberto Berni Canani
Microorganisms 2026, 14(1), 150; https://doi.org/10.3390/microorganisms14010150 - 9 Jan 2026
Cited by 1 | Viewed by 1559
Abstract
The human gut microbiota plays a key role in health and disease across the lifespan and is shaped by complex intrinsic and extrinsic factors. Dysbiosis is increasingly recognized as a contributor to a wide range of clinical conditions, with diarrhoea—particularly antibiotic-associated diarrhoea—representing an [...] Read more.
The human gut microbiota plays a key role in health and disease across the lifespan and is shaped by complex intrinsic and extrinsic factors. Dysbiosis is increasingly recognized as a contributor to a wide range of clinical conditions, with diarrhoea—particularly antibiotic-associated diarrhoea—representing an early clinical marker of microbiota disruption. This narrative review summarizes current evidence on the probiotic yeast Saccharomyces boulardii CNCM I-745 and its clinical applications in both paediatric and adult populations. Available clinical data support its safety and efficacy in the prevention and management of gastrointestinal disorders, particularly diarrhoeal conditions, and suggest a potential role in promoting microbiota resilience. Key mechanisms of action, safety considerations, and findings from randomized controlled trials and meta-analyses are discussed. However, current data remains limited by heterogeneity among studies and a lack of long-term, mechanistic data, highlighting the need for further well-designed studies to clarify its role across different clinical settings. Full article
(This article belongs to the Special Issue Gut Microbiota and Metabolic Disease Pathogenesis)
Show Figures

Figure 1

Back to TopTop